Scarica l'app Stockscreener
25.77
4.52%
-1.22
Dopo l'orario di chiusura:
25.60
-0.17
-0.66%
Precedente Chiudi:
$26.99
Aprire:
$26.22
Volume 24 ore:
830.91K
Relative Volume:
0.91
Capitalizzazione di mercato:
$1.52B
Reddito:
$13.05M
Utile/perdita netta:
$-60.54M
Rapporto P/E:
-22.22
EPS:
-1.16
Flusso di cassa netto:
$-37.82M
1 W Prestazione:
-11.44%
1M Prestazione:
-14.07%
6M Prestazione:
-42.76%
1 anno Prestazione:
-27.20%
Intervallo 1D:
$24.30
$26.25
Intervallo di 1 settimana:
$24.30
$28.83
Portata 52W:
$24.30
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Confronta JANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
25.77 | 1.52B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
(JANX) Investment Report - news.stocktradersdaily.com
Janux Therapeutics stock hits 52-week low at $28.92 By Investing.com - Investing.com South Africa
Janux Therapeutics stock hits 52-week low at $28.92 - Investing.com India
Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? - Yahoo Finance
Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March - MSN
We're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To Grow - Yahoo Finance
12 Best Up and Coming Stocks to Buy According to Wall Street Analysts - Insider Monkey
First Week of JANX November 21st Options Trading - Nasdaq
RA Capital Management, L.P. Increases Stake in Janux Therapeutics Inc - GuruFocus.com
Insiders Are Spending Big: 15 Stocks Leading in March - Insider Monkey
Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey
10 Worst High-Risk High-Reward Growth Stocks To Buy - Insider Monkey
Commit To Buy Janux Therapeutics At $25, Earn 30% Annualized Using Options - Nasdaq
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical - openPR
Janux Therapeutics (NASDAQ:JANX) Shares Gap Up Following Insider Buying Activity - Defense World
Insiders Are Loading Up on These 4 Biotech Stocks Now - 24/7 Wall St.
(JANX) Proactive Strategies - news.stocktradersdaily.com
JANX stock touches 52-week low at $29.62 amid market shifts By Investing.com - Investing.com South Africa
JANX stock touches 52-week low at $29.62 amid market shifts - Investing.com India
Sunday Insider Moves: Top Buys and Sells from Friday’s Disclosures By Investing.com - Investing.com Australia
Sunday Insider Moves: Top Buys and Sells from Friday’s Disclosures - Investing.com India
Ra Capital Management, L.P. Purchases 341,742 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock - Defense World
Ra Capital Management, L.P. Purchases 110,206 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock - Defense World
Major Investment Alert: Janux Therapeutics Stock Sees Massive Buy-In! - TipRanks
Proficio Capital Partners LLC Invests $1.35 Million in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Ra capital management buys $25.3 million in Janux therapeutics stock By Investing.com - Investing.com Australia
Ra capital management buys $25.3 million in Janux therapeutics stock - Investing.com
HC Wainwright Has Pessimistic Outlook of JANX Q1 Earnings - Defense World
Janux Therapeutics (JANX) Projected to Post Quarterly Earnings on Friday - Defense World
Janux Therapeutics chief business officer sells shares for $107,174 By Investing.com - Investing.com South Africa
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Janux Therapeutics chief business officer sells shares for $107,174 - Investing.com India
Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently - Insider Monkey
JANUX THERAPEUTICS Earnings Preview: Recent $JANX Insider Trading, Hedge Fund Activity, and More - Nasdaq
10 Stocks With At Least $30 Million In Insider Spending Recently - Insider Monkey
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Rhumbline Advisers - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Holdings Lifted by New York State Common Retirement Fund - Defense World
Janux Therapeutics (NASDAQ:JANX) Given “Buy” Rating at HC Wainwright - Defense World
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week Low on Analyst Downgrade - Defense World
Promising Developments and Strong Financial Position Support Buy Rating for Janux Therapeutics - TipRanks
Janux Therapeutics’ (JANX) Outperform Rating Reiterated at Wedbush - Defense World
Positive Outlook for Janux Therapeutics Inc. Driven by Unique Therapeutic Potential and Strategic Advantages - TipRanks
Janux Therapeutics price target lowered to $41 from $62 at Scotiabank - Yahoo Finance
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):